ERBB2 and breast carcinoma: It was granted accelerated approval by the U.S. Food and Drug Administration based on its phase II pathologic complete response rate (pCR) in neoadjuvant treatments of HER2-positive early-stage, inflammatory, and locally advanced breast cancer with trastuzumab and docetaxel [34].